Table 1: Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation / CMAJ

Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation

Table 1: Mean age of patients with nonvalvular atrial fibrillation (NVAF) and of control subjects in sinus rhythm

Patient group No.
of patients Mean age
(and SD*), yr

NVAF patients

   Group 1: no prior embolic event, not taking warfarin 29 73.0  (9.9)†

   Group 2: no prior embolic event, taking warfarin 21 70.3  (9.4)

   Group 3: prior embolic event, taking warfarin 24 74.3  (6.9)‡

Control subjects

   No prior thrombotic stroke 29 65.7  (11.5)

   Prior thrombotic stroke 11 64.7  (14.0)

*SD = standard deviation.
†p = 0.002, compared with control subjects without history of stroke.
‡p < 0.001, compared with control subjects without history of stroke.

[Return to text]

| CMAJ September 15, 1997 (vol 157, no 6) / JAMC le 15 septembre 1997 (vol 157, no 6) |

CMA Webspinners / Les fileurs du Web de l'AMC

Table 1: Mean age of patients with nonvalvular atrial fibrillation (NVAF) and of control subjects in sinus rhythm
Patient group	No. of patients	Mean age (and SD*), yr
NVAF patients
Group 1: no prior embolic event, not taking warfarin	29	73.0 (9.9)†
Group 2: no prior embolic event, taking warfarin	21	70.3 (9.4)
Group 3: prior embolic event, taking warfarin	24	74.3 (6.9)‡
Control subjects
No prior thrombotic stroke	29	65.7 (11.5)
Prior thrombotic stroke	11	64.7 (14.0)
*SD = standard deviation. †p = 0.002, compared with control subjects without history of stroke. ‡p < 0.001, compared with control subjects without history of stroke.